A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
Latest Information Update: 22 Jan 2025
Price :
$35 *
At a glance
- Drugs Ifinatamab deruxtecan (Primary) ; Docetaxel; Irinotecan; Paclitaxel
- Indications Carcinoma; Oesophageal cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms IDeate-Esophageal01
- Sponsors Daiichi Sankyo Company
- 22 Jan 2025 New trial record